Medindia

X

Dermatologists Continue to Use Enbrel Over Humira as First-Line Biologic Therapy for the Treatment of Psoriasis

Thursday, September 18, 2008 General News J E 4
Advertisement
WALTHAM, Mass., Sept. 18 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that 77 percent of surveyed dermatologists nameAmgen/Wyeth/Takeda's Enbrel as their preferred first-line biologic therapy.The critical factors driving surveyed dermatologists' use of Enbrel ahead ofAbbott/Eisai's Humira are its perceived better side-effect/safety profile andwealth of long-term safety data, as well as their own familiarity with thedrug.

The new report entitled Treatment Algorithms in Psoriasis finds that 60percent of surveyed dermatologists choose Enbrel as a first-line biologictherapy because of their familiarity and experience with the drug; 59 percentchoose Enbrel because of their perception that its side-effect/safety profileis superior to that of Humira. On the other hand, surveyed dermatologists whochoose to prescribe Humira over Enbrel do so for very different reasons.Fifty-one percent of surveyed dermatologists state that Humira's less frequentdosing (once every two weeks versus once or twice weekly) influences theirchoice of this agent over Enbrel as a first-line biologic therapy and 45percent prescribe Humira as a first-line biologic drug because of its betterefficacy in clearing psoriatic plaques.

"Enbrel and Humira each garner more second- and third-line patient sharein our current analysis compared with our 2007 report," said Madhuri Borde,Ph.D., analyst at Decision Resources. "While Enbrel leads Humira in each lineof therapy, our physician survey data suggests that Humira's growingpenetration of early-line treatment in psoriasis will continue through 2010,in part at the expense of declining use of Genentech/Merck Serono's T-cellmodulator Raptiva."

The report also finds that 66 percent of surveyed dermatologists who arefamiliar with Centocor/ Medarex/Janssen-Cilag's interleukin-12/23 inhibitorStelara (ustekinumab) plan to prescribe the drug when it becomes available.Stelara is generating excitement among interviewed experts because of its highresponse rates and the potential for long-term remissions. Surveyeddermatologists who expect to incorporate Stelara into their therapeuticarsenal say that the greatest percentage of its total use will stem fromsecond-line therapy. This physician group estimates that 20 percent of theiruse of Stelara will be in first-line therapy, whereas 40 percent of theirprescriptions for the drug will be as a second-line treatment.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the mostextensive claims-based longitudinal patient-level data from PharMetrics(R) toprovide exceptional insight into physicians' prescribing trends and thefactors that drive therapy product choice, from diagnosis through multiplecourses of treatment, for a specific disease.

About Decision Resources

Decision Resources ( http://www.DecisionResources.com ) is a world leaderin market research publications, advisory services and consulting designed tohelp clients shape strategy, allocate resources and master their chosenmarkets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offersbest-in-class, high-value information and insights on important sectors of thehealthcare industry. Clients rely on this analysis and data to make informeddecisions. Please visit Decision Resources, Inc. athttp://www.DecisionResourcesInc.com .

All company, brand or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
SuperGen to Present at UBS Global Life Sciences Co...
S
IDIS to Sponsor Inaugural Conference on Pre-Launch...